Cryoport (NASDAQ:CYRX) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Cryoport (NASDAQ:CYRX) in a research note released on Thursday morning, Marketbeat reports. The firm issued a buy rating and a $11.00 target price on the stock.

Several other research analysts have also recently weighed in on CYRX. UBS Group boosted their price target on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Roth Mkm lowered their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Stock Performance

CYRX stock opened at $7.86 on Thursday. The stock has a market capitalization of $388.53 million, a PE ratio of -2.33 and a beta of 1.62. Cryoport has a 12-month low of $5.32 and a 12-month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock’s 50 day simple moving average is $7.39 and its 200 day simple moving average is $8.02.

Insider Buying and Selling at Cryoport

In related news, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the transaction, the chief executive officer now directly owns 731,897 shares in the company, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock worth $735,673 in the last three months. 10.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its holdings in Cryoport by 5.5% during the third quarter. Franklin Resources Inc. now owns 385,619 shares of the company’s stock valued at $3,127,000 after purchasing an additional 20,077 shares in the last quarter. Barclays PLC lifted its stake in shares of Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock valued at $660,000 after buying an additional 59,582 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Cryoport by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock worth $8,902,000 after buying an additional 38,520 shares during the period. Bullseye Asset Management LLC increased its stake in Cryoport by 58.7% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock worth $1,737,000 after buying an additional 79,244 shares in the last quarter. Finally, State Street Corp raised its holdings in Cryoport by 2.8% during the third quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after acquiring an additional 27,438 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.